Latest Regulatory News

News Corporation has updated its financial statements to reflect the sale of Foxtel, reporting a 3% revenue increase in fiscal 2024 driven by its Digital Real Estate Services and Book Publishing segments, alongside a 66% rise in net income from continuing operations.

Commonwealth Bank of Australia reports a 45 basis point increase in its CET1 capital ratio for Q1 2025, driven by earnings despite rising risk-weighted assets. The bank maintains strong liquidity and leverage ratios above regulatory minimums.

Commonwealth Bank of Australia reported a stable $2.6 billion cash profit for the quarter, maintaining strong capital and dividend payouts despite slight increases in consumer arrears and corporate credit risks.

Peak Rare Earths Limited has voluntarily suspended trading of its shares pending a significant announcement on potential corporate and capital raising transactions expected by 16 May 2025.

Highfield Resources has inked a non-binding letter of intent with Qinghai Salt Lake, a China Minmetals subsidiary, for a US$300 million equity investment aimed at fast-tracking its potash projects in Spain and Canada.

Ramelius Resources has obtained regulatory relief from ASIC, extending the deadline to make its takeover offer for Spartan Resources by an additional 31 days, a move that could influence the pace and outcome of the acquisition.

Mount Burgess Mining NL has voluntarily suspended trading of its shares on the ASX pending a court ruling on the validity of a recent cleansing notice tied to new share issuance.

Nanoveu Limited has increased its capital raise by $310,000, bringing the total placement to $3.02 million, with updated details on share and option issuances including conditional allocations to its Executive Chairman.

OM Holdings has agreed to sell its 26% interest in Ntsimbintle Mining to Exxaro Resources for US$101.4 million, marking a strategic shift to refocus capital on core operations while maintaining a commercial partnership.

Neuren Pharmaceuticals has received official FDA minutes confirming the primary endpoints for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, reinforcing the positive signals from earlier studies.

PolyNovo’s NovoSorb BTM technology has demonstrated promising first-in-human results as a novel delivery platform for pancreatic islet cell transplants in Type 1 diabetes, potentially redefining treatment approaches.

RPMGlobal Holdings reveals a significant reduction in corporate costs for FY2026 following the divestment of its Advisory business, setting the stage for a leaner operational focus on its core software segment.